• Explore /
  • Poster
  • / Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).

Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).

Abstract Poster

Authors

Deaglan McHugh

Deaglan Joseph McHugh

Memorial Sloan Kettering Cancer Center, New York, NY

Deaglan Joseph McHugh , Samuel Funt , Deborah Silber , Andrea Knezevic , Sujata Patil , Devon O'Donnell , Stephanie Tsai , Victor E. Reuter , Joel Sheinfeld , Brett Stewart Carver , Robert J. Motzer , Dean F. Bajorin , George J. Bosl , Darren R. Feldman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Germ Cell/Testicular

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4552)

DOI

10.1200/JCO.2018.36.15_suppl.4552

Abstract #

4552

Poster Bd #

378

Abstract Disclosures

Similar Posters

Poster

2018 Genitourinary Cancers Symposium

Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).

Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).

First Author: Deaglan Joseph McHugh

First Author: Samuel Funt

First Author: Chunkit Fung

First Author: Adam Uprichard